Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Ferrand

Showing results (81-90 of 102) with videos related to

Pageof 11
Sort By:
Cancer Research|December 6, 2018
CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T CellsWalid Warda, Fabrice Larosa, Mathieu Neto Da Rocha, et al.
Blood|January 22, 2010
Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistanceCarole Henry, Marina Deschamps, Pierre-Simon Rohrlich, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 7, 2014
T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety studyGéraldine Gallot, Solène Vollant, Soraya Saïagh, et al.
British Journal of Haematology|April 25, 2009
Extended diagnostic criteria for plasmacytoid dendritic cell leukaemiaFrancine Garnache-Ottou, Jean Feuillard, Christophe Ferrand, et al.
Blood|December 11, 2012
High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemiaMarlène Pasquet, Christine Bellanné-Chantelot, Suzanne Tavitian, et al.
Bulletin Du Cancer|July 13, 2021
[Immunomonitoring of patients treated with CAR-T cells for hematological malignancy: Guidelines from the CARTi group and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Marie Thérèse Rubio, Pauline Varlet, Vincent Allain, et al.
Blood|September 25, 2004
Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cellsFrancine Garnache-Ottou, Laurence Chaperot, Sabeha Biichle, et al.
Blood|August 22, 2013
Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopeniaSylvain Audia, Maxime Samson, Matthieu Mahévas, et al.
Journal for Immunotherapy of Cancer|July 8, 2022
Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemiaRim Trad, Walid Warda, Vincent Alcazer, et al.
Bone Marrow Transplantation|January 25, 2025
Identification of the conditions and minimum requirements necessary for the release of autologous fresh CAR T-cell products under hospital exemption: a position paper from the WP-bioproduction of the UNITC consortiumOlivier Boyer, Daniele Bensoussan, Halvard Bönig, et al.
Pageof 11

Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
Cancer Research|December 6, 2018
CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T CellsWalid Warda, Fabrice Larosa, Mathieu Neto Da Rocha, et al.
Blood|January 22, 2010
Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistanceCarole Henry, Marina Deschamps, Pierre-Simon Rohrlich, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 7, 2014
T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety studyGéraldine Gallot, Solène Vollant, Soraya Saïagh, et al.
British Journal of Haematology|April 25, 2009
Extended diagnostic criteria for plasmacytoid dendritic cell leukaemiaFrancine Garnache-Ottou, Jean Feuillard, Christophe Ferrand, et al.
Blood|December 11, 2012
High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemiaMarlène Pasquet, Christine Bellanné-Chantelot, Suzanne Tavitian, et al.
Bulletin Du Cancer|July 13, 2021
[Immunomonitoring of patients treated with CAR-T cells for hematological malignancy: Guidelines from the CARTi group and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Marie Thérèse Rubio, Pauline Varlet, Vincent Allain, et al.
Blood|September 25, 2004
Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cellsFrancine Garnache-Ottou, Laurence Chaperot, Sabeha Biichle, et al.
Blood|August 22, 2013
Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopeniaSylvain Audia, Maxime Samson, Matthieu Mahévas, et al.
Journal for Immunotherapy of Cancer|July 8, 2022
Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemiaRim Trad, Walid Warda, Vincent Alcazer, et al.
Bone Marrow Transplantation|January 25, 2025
Identification of the conditions and minimum requirements necessary for the release of autologous fresh CAR T-cell products under hospital exemption: a position paper from the WP-bioproduction of the UNITC consortiumOlivier Boyer, Daniele Bensoussan, Halvard Bönig, et al.
Pageof 11